Beyond Prevnar

Frazier Healthcare Partners had been tracking SutroVax Inc.'s progress since it spun out of Sutro Biopharma Inc. in 2013 and came on board to co-lead the company's $60 million series B round after preclinical proof-of-concept data materialized for the lead conjugate vaccine.

The round closed March 21. Pivotal bioVenture Partners co-led with Frazier. Existing investors Abingworth, Longitude Capital, Roche Venture Fund and CTI Life Sciences participated, and also topped off SutroVax's series A with $4 million, bringing the total of that round to $26 million...